Rallybio

Update in progress

RLYB (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Rallybio is a clinical‑stage biotechnology company focused on developing therapies for severe and rare diseases. Its lead candidate, RLYB116, inhibits complement component 5 (C5) and has completed a Phase 1 trial; RLYB332 is a preclinical antibody for severe anemia with ineffective erythropoiesis and iron overload. The company partners with AbCellera and Johnson & Johnson, and was founded in 2018 in New Haven, Connecticut.

Company score

Sentiment: 0.01; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.06; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.00; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqCM (NCM)
LocationUnited States
CEODr. Stephen Uden M.D., MBBS
Founded2018
Employees7
Websitewww.rallybio.com

Identifiers

ISINUS75120L1008
FIGIBBG011PFKF54
CUSIP75120L100
CIK0001739410